S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors

06-May-2010 - S*BIO Pte Ltd and Onyx Pharmaceuticals, Inc. announced the expansion of their development collaboration and option and license commercialization agreement for S*BIO’s novel JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively. The expanded agreement builds upon ...

Bayer and Onyx Initiate Phase III Trial of Nexavar in Patients with Non-Responsive Thyroid Cancer

27-Oct-2009 - Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that the companies have begun enrolling patients in an international Phase III trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic ...

Nexavar in Combination with Chemotherapy Shown To Extend Progression-Free Survival in Patients with Advanced Breast Cancer

Statistically Significant Results Reported from a Phase II Study Combining Two Oral Cancer Therapies

24-Jul-2009 - Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that their first cooperative group-sponsored randomized Phase II trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar® (sorafenib) tablets in combination ...

BTG licenses novel anticancer compound to Onyx Pharmaceuticals

BTG to receive $13m upfront plus potential milestones of up to $307m and sales royalties

11-Nov-2008 - BTG plc announced it has granted worldwide rights to Onyx Pharmaceuticals, Inc. to develop and commercialise BTG’s novel anticancer compound, BGC 945. Under the terms of the agreement, BTG will receive an upfront payment of $13m and has the potential to receive development milestone payments of ...

Onyx Pharmaceuticals Names Juergen Lasowski, Ph.D. as Senior Vice President of Corporate Development

19-Aug-2008 - Onyx Pharmaceuticals, Inc. announced the appointment of Dr. Juergen Lasowski as senior vice president of corporate development. In this role, Dr. Lasowski will lead business development activities for the company, assessing opportunities to potentially expand and diversify Onyx's ...

Bayer and Onyx Announce Nexavar® (sorafenib tosylate) Tablets as Global Trade Name for Investigational Cancer Treatment

02-Nov-2005 - Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals, Inc. announced the selection of Nexavar® (sorafenib tosylate) Tablets as the global trade name for sorafenib, the oral investigational drug under FDA review for the treatment of advanced renal cell carcinoma (RCC), or kidney ...